

Special Issue

Management of Osteoarthritis Pain

Message from the Guest Editor

Osteoarthritis (OA) is the most common joint disorder with more than 500 million people (7% of the global population) being affected by the disease worldwide. Pain is the predominant symptom of OA and is what usually leads those with OA to seek medical care. Recent OA research has improved our understanding of the pathophysiology of the disease. Specifically, the identification of the TGF- β and Wnt/ β -catenin signaling pathways has provided hope for the discovery of a disease-modifying osteoarthritis drug. In recent years, several novel agents have emerged as potential treatment alternatives to improve pain, stiffness, and function with the possibility of altering the disease progression. This Special Issue will focus on the current and future management of OA pain. The factors dictating the onset and progression of the disease will be reviewed, as will the current clinically approved methods for its treatment and diagnosis. We will also present research that elaborates on the current challenges and opportunities for the development and application of novel potentially disease-modifying medicines for the treatment of OA pain.

Guest Editor

Dr. Leslie A. Tive

Investiga Tive, LLC, 15 Chapin Trail, White Lake, New York, NY 12786, USA

Deadline for manuscript submissions

20 July 2025



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/158186

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

[jpm](https://jpm.mdpi.com)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).